Sennoside 是一种可于 Senna (Cassia angustifolia) 中发现的、口服有效的凋亡 (apoptosis) 诱导剂和刺激性泻药,它通过介导结肠上皮细胞凋亡的通路诱导野生型 p53 和 p21/WAF 过表达,刺激结肠蠕动,将水、钠、氯的净吸收逆转为分泌并促进钾和钙的分泌,增加小分子的细胞旁通透性,加速结肠转运并软化粪球,可用于便秘、结肠黑变病和结直肠癌的相关研究。
产品编号: MS-I13915 CAS No.: 517-43-1 分子式: C42H38O20 分子量: 862.74
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Sennoside 是一种可于 Senna (Cassia angustifolia) 中发现的、口服有效的凋亡 (apoptosis) 诱导剂和刺激性泻药,它通过介导结肠上皮细胞凋亡的通路诱导野生型 p53 和 p21/WAF 过表达,刺激结肠蠕动,将水、钠、氯的净吸收逆转为分泌并促进钾和钙的分泌,增加小分子的细胞旁通透性,加速结肠转运并软化粪球,可用于便秘、结肠黑变病和结直肠癌的相关研究。

生物实验数据

生物活性 Sennoside is an orally active apoptosis inducer and stimulant laxative found in Senna (Cassia angustifolia) that induces overexpression of wild-type p53 and p21/WAF through a pathway mediating apoptosis in colonic epithelial cells, stimulates colonic motility, reverses the net absorption of water, sodium, and chloride to secretion, promotes potassium and calcium secretion, increases paracellular permeability to small molecules, accelerates colonic transit, and softens fecal pellets, and can be used in research related to constipation, melanosis coli, and colorectal cancer.
体内研究
(In Vivo)

Sennoside (50 mg/kg;口服;单次给药) 可诱导大鼠结肠中 H2O、Na+ 和 Cl− 的净吸收向净分泌呈时间依赖性逆转,在 6 小时时效应达到峰值;至 12 小时时,Cl− 恢复为净吸收状态,而 K+ 和 Ca2+ 的净分泌水平升高并持续至 24 小时仍维持高位。
Sennoside (50 mg/kg;口服;单次给药) 在 6 小时时短暂升高细胞旁通透性但未显著损伤上皮细胞或改变 cAMP 通路活性,且 Na+, K+-ATPase 的活性总体未受影响。

Animal Model: Wistar (female, ~200 g body weight)
Dosage: 50 mg/kg
Administration: p.o.; single dose
Result: Showed no change in net H2O, Na+, Cl-, and K+ absorption/secretion from controls at 2 and 4 hours post-treatment.
Reversed net H2O, Na+, and Cl- absorption to net secretion at 6 hours (H2O: -0.34 mL/10 cm colon/h, Na+: -44 μmol/10 cm colon/h, Cl-: -32 μmol/10 cm colon/h; all p ≤ 0.001 vs controls).
Increased net K+ secretion to -15.3 μmol/10 cm colon/h at 6 hours (p ≤ 0.05 vs controls).
Increased net Ca2+ secretion to -1.14 μmol/10 cm colon/h at 6 hours (p ≤ 0.01 vs controls).
Increased paracellular permeability to 3-fold higher than controls at 6 hours (-336 μl/10 cm colon/h, p ≤ 0.001 vs controls).
Showed persistent but diminished net H2O and Na+ secretion at 12 hours (H2O: -0.51 mL/10 cm colon/h, Na+: -13 μmol/10 cm colon/h; both p ≤ 0.001 vs controls), while Cl- returned to net absorption (9 μmol/10 cm colon/h, p ≤ 0.001 vs controls).
Increased net K+ secretion to -22.8 μmol/10 cm colon/h at 12 hours (p ≤ 0.001 vs controls).
Increased net Ca2+ secretion to -0.97 μmol/10 cm colon/h at 12 hours (p ≤ 0.001 vs controls).
Showed persistent reduced net H2O secretion at 24 hours (-0.20 mL/10 cm colon/h, p ≤ 0.001 vs controls), while Na+ and Cl- showed net absorption (Na+: 18 μmol/10 cm colon/h, Cl-: 34 μmol/10 cm colon/h; both p ≤ 0.001 vs controls).
Increased net K+ secretion to -23.9 μmol/10 cm colon/h at 24 hours (p ≤ 0.001 vs controls).
Increased net Ca2+ secretion to -1.18 μmol/10 cm colon/h at 24 hours (p ≤ 0.001 vs controls).
Showed no significant increase in LDH leakage into the colon lumen at any time point post-treatment.
Showed unchanged Na+, K+-ATPase activity at 4 and 6 hours, with a statistically significant but inconsistent reduction at 24 hours (568 nmol Pi/mg protein/10 min, p ≤ 0.001 vs controls).
Showed unchanged colon mucosal cAMP content and phosphodiesterase activity at 6 hours post-treatment.
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT00902031University of Alberta|College of Family Physicians of Canada|Covenant Health, Canada|Capital Care
Constipation|Palliative Care
2006-04NA

化学信息

分子量 862.74
分子式 C42H38O20
CAS No. 517-43-1

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础